Head to Head Comparison: Tempus AI (TEM) and The Competition

Tempus AI (NASDAQ:TEM – Get Free Report) is one of 233 publicly-traded companies in the “Healthcare Providers & Services” industry, but how does it contrast to its competitors? We will compare Tempus AI to similar businesses based on the strength of its valuation, earnings, analyst recommendations, institutional ownership, dividends, risk and profitability.

Valuation and Earnings

This table compares Tempus AI and its competitors revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Tempus AI $1.27 billion -$245.03 million -61.09
Tempus AI Competitors $21.12 billion $301.67 million -1.61

Tempus AI’s competitors have higher revenue and earnings than Tempus AI. Tempus AI is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Tempus AI has a beta of 3.61, suggesting that its stock price is 261% more volatile than the S&P 500. Comparatively, Tempus AI’s competitors have a beta of 0.98, suggesting that their average stock price is 2% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and price targets for Tempus AI and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tempus AI 1 10 11 0 2.45
Tempus AI Competitors 1880 7755 13395 833 2.55

Tempus AI currently has a consensus target price of $79.37, indicating a potential upside of 22.56%. As a group, “Healthcare Providers & Services” companies have a potential upside of 12.63%. Given Tempus AI’s higher possible upside, analysts clearly believe Tempus AI is more favorable than its competitors.

Profitability

This table compares Tempus AI and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Tempus AI -12.54% -47.00% -9.44%
Tempus AI Competitors -7.86% -135.43% -1.59%

Institutional & Insider Ownership

24.2% of Tempus AI shares are owned by institutional investors. Comparatively, 56.7% of shares of all “Healthcare Providers & Services” companies are owned by institutional investors. 24.3% of Tempus AI shares are owned by insiders. Comparatively, 14.9% of shares of all “Healthcare Providers & Services” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Tempus AI competitors beat Tempus AI on 9 of the 13 factors compared.

About Tempus AI

(Get Free Report)

Tempus AI is a technology company focused on applying data and artificial intelligence to healthcare, with an emphasis on precision medicine. Its platform combines clinical and molecular data to help physicians make more informed treatment decisions and support life-sciences research. The company provides genomic sequencing and other diagnostic testing, software tools for analyzing patient data, and services that help identify clinical trial opportunities. Its work spans oncology and other areas of medicine, and it collaborates with healthcare providers and pharmaceutical and biotechnology companies.

Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.